Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The treatment of a specific subtype of highly malignant brain tumor (called "glioblastoma" or "glioblastoma multiforme") consists of neurosurgical resection, followed by radiotherapy and mostly chemotherapy as well. Increased extent of tumor resection is associated with prolonged survival. The standard treatment uses conventional neuronavigation systems to increase extent of tumor resection. However, the quality of this form of neuronavigation decreases throughout surgery because of "brain shift". This is caused by edema, loss of cerebrospinal fluid and tumor resection. A new form of neuronavigation uses intraoperative MRI to compensate for brain shift, and to check for the presence of residual tumor that can be removed.
This study aims to compare the extent of glioblastoma resection between the standard treatment and intraoperative MRI.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Conventional Neuronavigation | Active Comparator | Standard form of neuronavigation: based on preoperative MRI without intraoperative correction for brain shift |
|
| Intraoperative MRI | Experimental | Standard neuronavigation plus intraoperative MRI to correct for brain shift |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Stealth Station | Device | Neuronavigation based on preoperative MRI |
|
| Measure | Description | Time Frame |
|---|---|---|
| Difference in Residual tumor volume | <72h after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Complications, Clinical Performance, and Quality of Life | 3 months after surgery | |
| Survival | 2 years after surgery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Henk van Santbrink, MD, PhD | Maastricht University Medical Center | Principal Investigator |
| Didier Martin, MD, PhD | Centre Hospitalier Universitaire de Liege | Principal Investigator |
| Koo van Overbeeke, MD, PhD | Maastricht University Medical Center | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier Universitaire de Liege | Liège | Belgium | ||||
| Maastricht University Medical Center |
Not provided
Not provided
Not provided
Not provided
Not provided
| PoleStar N20 | Device | Intraoperative MRI guided surgery |
|
|
| Maastricht |
| Netherlands |
| ID | Term |
|---|---|
| D005909 | Glioblastoma |
| ID | Term |
|---|---|
| D001254 | Astrocytoma |
| D005910 | Glioma |
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |
Not provided
Not provided